[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
:: Volume 31, Issue 3 (Fall 2021) ::
MEDICAL SCIENCES 2021, 31(3): 284-289 Back to browse issues page
Preparation and in-vitro evaluation of sustained release glatiramer solid lipid nanoparticles
Fatemeh Ghashghaee1, Solmaz Ghaffari 2
1- Department of Medical Chemistry, Faculty of Chemistry, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
2- 2Department of Pharmaceutics, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran 3 Dental Material Research Center, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran , soligh@yahoo.com
Abstract:   (293 Views)
Background: Multiple sclerosis (MS), which is associated with the destruction of the myelin of the nerve cells, causes many motor-sensory problems and disrupts their quality of life. One of the remedies for this disease is glatiramer, which is injected daily as a peptide at a dose of 20 mg, tolerating of it for a long period of time is too difficult due to irritation of injection site. In this study with using nanotechnology tried to control the release rate of the drug to increase the interval of injections and consequently, patient’s tolerance.
Materials and methods: Glatiramer solid lipid nanoparticles (SLNs) were prepared using cholesterol as carrier by high shear homogenization technique. The particle size and zeta potential were investigated. The particle morphology was evaluated by SEM (Scanning Electron Microscopy) and finally the drug loading efficacy and drug release pattern were studied. To enhance the stability of the prepared nanoparticles, lyophilization was carried out by mannitol as cryoprotectant agent.
Results: The results showed that particles prepared with a size less than 300 nm and PDI: Polydispersity Index of less than 0.5, drug loading rate of over 74% and release over 6 days could be a good candidate for replacement of current treatment with this drug.
Conclusion: It seems that drug delivery of glatiramer with nanotechnology could provide a new solution for the problem of controlling MS with this drug in the future with more patient compliance.
Keywords: Multiple sclerosis, Nanotechnology, Glatiramer, Sustained release, Side Effects.
Full-Text [PDF 261 kb]   (150 Downloads)    
Semi-pilot: Experimental | Subject: Pharmacology
Received: 2020/01/22 | Accepted: 2020/06/1 | Published: 2021/09/1
References
1. 1) Kobelt G, Berg J, Atherly D, Hadjimichal O. Costs and Quality of Life in Multiple Sclerosis: A Cross Sectional Study in the United States. Neurology.2006:66:1696-1712. [DOI:10.1212/01.wnl.0000218309.01322.5c]
2. 2) Polman CH, et al. Diagnostic Criteria for Multiple Sclerosis: 2005 Revisions to the "McDonald Criteria". Ann Neurol. 2005:21:141-156. [DOI:10.1002/ana.20703]
3. 3) Kurtzke J. Rating Neurological Impairment in Multiple Sclerosis: An Expanded Disability Status Scale (EDSS). Neurology. 1983:33:1444-1452. [DOI:10.1212/WNL.33.11.1444]
4. 4) Wubgerchuck D, Noseworthy J, Weinshenkar B. Clinical Outcome Measures and Rating Scales in Multiple Sclerosis Trials. Mayo Clin Proc. 1997: 72: 1171-1179. [DOI:10.4065/72.11.1070]
5. 5) Gray O, Butzkueven H. Measurement of disability in multiple sclerosis. Neurol Asia. 2001: 13: 153-156.
6. 6) Keegan BM, Noseworthy JH. Multiple sclerosis. Annu Rev Med. 2002: 53: 215-312. [DOI:10.1146/annurev.med.53.082901.103909]
7. (7Editors: Smith B, et al Drug Class Review: Disease- modifying Drugs for Multiple Sclerosis: Final Update Report [Internet]. Source: Portland (OR): Oregon Health & Science University; 2001 Aug.
8. 8) Muller RH, Mehnert W, Lucks JS, Schwarz C, Zur Muehlen A, Weyhers H, Freitas C, drug delivery, Eur. J. Pharm. Biopharm. 1995(41): 62-69.
9. 9) Pardeike J, Hommoss A, Muller RH. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products, Int. J. Pharm. 2009: 114-117.
10. 10) Alihoseyni F, Ghaffari S, Dabirsiaghi AR, Haghighat S. Preparation and evaluation of ampicillin solid lipid nanoparticles. World J Pharm Sci 2014;2(9):914-20.
11. 11) Rao SM, Leo GJ, Ellington L, Nauertz T, Berbardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. II. Impact on employment and social functioning. Neurology. 1991(41) 692-696. [DOI:10.1212/WNL.41.5.692]
12. 12) 27) Ahmad El-Harati A. Influence of the Formulation for Solid Lipid Nanoparticles Prepared with a Memberane Contactor Pharmaceutical Development and Technology. 2006(11(2): 153-157. [DOI:10.1080/10837450600561182]
13. 13) Helgason T, Awad TS, Kristbergsson K, Mc Clements DJ, Weiss J. Effects of surface Science. 2009: 334 (1): 75-99. [DOI:10.1016/j.jcis.2009.03.012]
14. Kobelt G, Berg J, Atherly D, Hadjimichal O. Costs and Quality of Life in Multiple Sclerosis: A Cross Sectional Study in the United States. Neurology 2006:66:1696-1712. [DOI:10.1212/01.wnl.0000218309.01322.5c]
15. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005;58:840-6. [DOI:10.1002/ana.20703]
16. Kurtzke J. Rating Neurological Impairment in Multiple Sclerosis: An Expanded Disability Status Scale (EDSS). Neurology 1983:33:1444-1452. [DOI:10.1212/WNL.33.11.1444]
17. Wubgerchuck D, Noseworthy J, Weinshenkar B. Clinical Outcome Measures and Rating Scales in Multiple Sclerosis Trials. Mayo Clin Proc 1997: 72: 1171-1179. [DOI:10.4065/72.11.1070]
18. Gray O, Butzkueven H. Measurement of disability in multiple sclerosis. Neurol Asia 2001;13:153-156.
19. Keegan BM, Noseworthy JH. Multiple sclerosis. Annu Rev Med 2002;53:215-312. [DOI:10.1146/annurev.med.53.082901.103909]
20. Smith B, Carson S, Fu R, McDonagh M, Dana T, Chan BKS, et al. Drug Class Review: Disease-modifying Drugs for Multiple Sclerosis: Final Update 1 Report [Internet]. Portland (OR): Oregon Health & Science University; 2010.
21. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm 2000;50:161-77. [DOI:10.1016/S0939-6411(00)00087-4]
22. Pardeike J, Hommoss A, Muller RH. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm 2007: 114-117.
23. Alihoseyni F, Ghaffari S, Dabirsiaghi AR, Haghighat S. Preparation and evaluation of ampicillin solid lipid nanoparticles. World J Pharm Sci 2014;2:914-20.
24. Rao SM, Leo GJ, Ellington L, Nauertz T, Berbardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. II. Impact on employment and social functioning. Neurology 1991;41: 692-696. [DOI:10.1212/WNL.41.5.692]
25. El-Harati AA, Charcosset C, Fessi H. Influence of the formulation for solid lipid nanoparticles prepared with a membrane contactor. Pharm Dev Technol 2006;11:153-7. [DOI:10.1080/10837450600561182]
26. Helgason T, Awad TS, Kristbergsson K, Mc Clements DJ, Weiss J. Effect of surfactant surface coverage on formation of solid lipid nanoparticles (SLN). J. Colloid Interface Sci 2009; 334:75-81. [DOI:10.1016/j.jcis.2009.03.012]
Send email to the article author

Add your comments about this article
Your username or Email:

CAPTCHA



XML   Persian Abstract   Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Ghashghaee F, Ghaffari S. Preparation and in-vitro evaluation of sustained release glatiramer solid lipid nanoparticles. MEDICAL SCIENCES. 2021; 31 (3) :284-289
URL: http://tmuj.iautmu.ac.ir/article-1-1669-en.html


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 31, Issue 3 (Fall 2021) Back to browse issues page
فصلنامه علوم پزشکی دانشگاه آزاد اسلامی واحد پزشکی تهران Medical Science Journal of Islamic Azad Univesity - Tehran Medical Branch
Persian site map - English site map - Created in 0.04 seconds with 30 queries by YEKTAWEB 4355